SERVICES

We are now offering Beyfortus (Nirsevimab), a prescription medicine used to help prevent serious lung disease caused by RSV (Respiratory Syncytial Virus)

PLEASE read this notice in its entirety as it includes important details regarding how this product can protect infants during the upcoming RSV season. We have gathered relevant safety and medical information from the CDC, AAP, and ACIP to provide the most accurate data.

Nirsevimab (Beyfortus) is a monoclonal antibody product designed to protect infants and young children at increased risk from severe RSV disease. It is administered by intramuscular injection. It is long-acting, providing protection for at least 5 months (the average length of one season), and only one dose is recommended for an RSV season. However, immune protection will wane over time. All infants younger than 8 months who are born during – or entering – their first RSV season (typically October- March) should receive one dose of nirsevimab. For some children between the ages of 8 and 19 months who are at increased risk of severe RSV disease (eligibility will be discussed with your provider), a dose is recommended at the start of their second RSV season. Infants who are 8-19 months of age can receive one dose of nirsevimab during the RSV season if they have the following conditions:

• Children who have chronic lung disease from being born premature and are requiring medical therapy for their lung disease
• Children who are severely immunocompromised
• Children with cystic fibrosis who have severe disease
• American Indian and Alaska Native children

RSV infection can cause a variety of respiratory illnesses and symptoms in infants and young children. It most commonly causes a cold-like illness but can also cause lower respiratory infections like bronchiolitis and pneumonia.

Most infants and young children with RSV infection may have rhinorrhea and a decrease in appetite before any other symptoms appear. Cough usually develops 1 to 3 days later. Soon after the cough develops, sneezing, fever, and wheezing may occur. Symptoms in very young infants can include irritability, decreased activity, and/or apnea.

Most otherwise healthy infants and young children who are infected with RSV do not need hospitalization. Two to three percent of infants with RSV infection may need to be hospitalized. Those who are hospitalized may require oxygen, rehydration, and/or mechanical ventilation. Most improve with supportive care and are discharged in a few days.  Severe disease most commonly occurs in premature infants, infants younger than 12 months of age, young infants or children with chronic lung disease or a weakened immune system.

If you are interested in your infant receiving a Beyfortus injection we ask that you take the next steps to streamline this process and to help us maintain the appropriate supply of this medication:

• The cost of Beyfortus without insurance can be expensive. As a result, we encourage checking with your insurance to ensure this medication is covered. You can refer to CPT code 90380 and 90381 and Diagnosis Code Z29.11 when inquiring about coverage. Due to patient demand and time constraints on our staff, we are unable to contact your insurance company for you. We appreciate your understanding and patience regarding this matter.
• Send us a portal message or call to inform us you are interested and if your insurance covers the medication. We will review your infant’s chart for eligibility and if appropriate, will call to set up a nurse visit to administer the medication.
• If you are already scheduled for a well check or office visit, we can also discuss the option to administer the medication if available at that time. It is safe to administer Beyfortus along with any other regularly scheduled vaccines.

Please let us know if you have any questions during this process.

Sincerely,

Wildflower Pediatric Staff and Providers